Polyrizon (PLRZ) announced the filing of a divisional patent application with the Europe Patent Office for its Trap & Target platform technology. This application focuses exclusively on protecting the company’s advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. The T&T platform represents a significant advancement in intranasal drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients and addressing challenges in both local and systemic drug delivery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRZ:
- Polyrizon files to sell 0.5M shares of common stock for holders
- Polyrizon Raises $3.5 Million via Registered Direct Offering and Private Placement
- Polyrizon to acquire 20% stake in Colugo for up to $6M
- Biotech Alert: Searches spiking for these stocks today
- Polyrizon Taps Global CRO to Run Key Preclinical Safety Studies Ahead of First Clinical Trials